drugset / Trial / NCT02807207
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
RandomizedCrossoverTriple-blindOther
Summary
The primary objective is to evaluate the cardiac safety of a single oral dose (400 mg) of pacritinib compared to placebo on the QT calculated using the Fridericia correction (QTcF) interval in healthy subjects.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 400 mg | — |
| Subject | Pacritinib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.